NDAINTRAVENOUSPOWDER
Approved
Oct 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
DAPTOMYCIN (daptomycin) by Hikma. Approved for lipopeptide antibacterial [epc]. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Daptomycin is a lipopeptide antibiotic administered intravenously that works by disrupting bacterial cell membrane function. It is indicated for serious gram-positive infections including bacteremia, infective endocarditis, and complicated skin and soft tissue infections caused by susceptible organisms such as Staphylococcus aureus. The drug's antimicrobial activity correlates with the AUC/MIC ratio, making it particularly effective against resistant pathogens.
Peak
Daptomycin is in peak commercial lifecycle as an established IV antibiotic with moderate competitive pressure (score: 30), suggesting stable but not rapidly growing team needs.
Mechanism of Action
Pharmacologic Class:
Lipopeptide Antibacterial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)
Started Dec 2018
18 enrolled
BacteremiaSoft Tissue InfectionsSkin Diseases, Infectious
Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin
Started May 2014
12 enrolled
Drug InteractionsPharmacokinetics
Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)
Started Sep 2013
149 enrolled
Acute Hematogenous Osteomyelitis
Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
Started Nov 2012
82 enrolled
Bacteremia
Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia
Started May 2012
10 enrolled
Nosocomial InfectionHealthcare-associated Infection
Worked on DAPTOMYCIN at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.